← Back to headlines
Ozempic Patent Expiry: Indian pharma to launch affordable generics; diabetes care set to widen
The upcoming patent expiry for Ozempic in India is set to dramatically lower the cost of semaglutide, making this once-premium diabetes and weight-loss drug accessible to more patients. This shift could reshape the market, prompting earlier prescriptions and potentially altering societal views on weight management and body acceptance.
7 Mar, 07:47 — 7 Mar, 07:47
